Fluocinolone Acetonide clinical trials
Also written ILUVIEN and Retisert.
How each study uses Fluocinolone Acetonide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Fluocinolone Acetonide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Feb 1963 · SYNALAR · NDA 012787 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 11
Alimera Sciences (8) · Bausch & Lomb Incorporated (5) · Galderma R&D (2) · Sanjay Asrani (1) · Texas Retina Associates (1) · EyePoint Pharmaceuticals, Inc. (1) · Glenn Jaffe (1) · Association for Innovation and Biomedical Research on Light and Image (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Corticosteroids source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Fluocinolone Acetonide.
- Jun 2027A Study of Yutiq Steroid Insert During Glaucoma Tube Implant SurgeryEarly Phase 1 · Sanjay Asrani
Studies
Open first, then newest update. How each study uses Fluocinolone Acetonide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyRecruitingPhase 3Jaeb Center for Health ResearchNCT05844982Written as fluocinolone acetonideHow we know
- Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular OedemaRecruitingPhase 4Centre Hospitalier Universitaire DijonNCT04910503Written as Fluocinolone Acetonide Intravitreal ImplantHow we know
- A Study of Yutiq Steroid Insert During Glaucoma Tube Implant SurgeryActive, not recruitingEarly Phase 1Sanjay AsraniNCT04918121Written as Yutiq 0.18 MG Drug ImplantHow we know
- The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior SegmentCompletedPhase 3Texas Retina AssociatesNCT05486468Written as Yutiq 0.18 MG Drug ImplantHow we know
- A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)Active, not recruitingPhase 4Alimera SciencesNCT04469595Written as Iluvien 0.19 MG Drug ImplantHow we know
- Combined Ranibizumab and Iluvien for Diabetic Macular OedemaWithdrawnPhase 2/3Imperial College LondonNCT03784443Written as Iluvien 0.19 MG Drug ImplantHow we know
- Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in MelasmaTerminatedPhase 4Galderma R&DNCT00669071Written as Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%How we know
- Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for MelasmaCompletedPhase 4Galderma R&DNCT00472966Written as Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peelsHow we know
- Phase 4 IOP Signals Associated With ILUVIEN®CompletedPhase 4Alimera SciencesNCT02424019Written as ILUVIEN 0.19 MGHow we know
- Steroids for Early Treatment of Radiation RetinopathyWithdrawnPhase 2/3The Cleveland ClinicNCT03238157Written as Fluocinolone Acetonide (FA) implantHow we know
- Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior UveitisCompletedPhase 3EyePoint Pharmaceuticals, Inc.NCT02746991Written as FAI InsertHow we know
- Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or PanuveitisCompletedPhase 1Glenn JaffeNCT01781936Written as Fluocinolone AcetonideHow we know
- Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) StudyWithdrawnPhase 4Johns Hopkins UniversityNCT02902744Written as ILUVIEN®How we know
- A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema PatientsCompletedPhase 4Association for Innovation and Biomedical Research on Light and ImageNCT02359526Written as IlUVIENHow we know
- A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid TherapyCompletedPhase 4Alimera SciencesNCT02472366Written as ILUVIENHow we know
- Fluocinolone Acetonide Intravitreal Inserts in Geographic AtrophyTerminatedPhase 2Alimera SciencesNCT00695318Written as Fluocinolone AcetonideHow we know
- Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in RetinaTerminatedPhase 2Alimera SciencesNCT00770770Written as Fluocinolone AcetonideHow we know
- Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension StudyCompletedPhase 3Alimera SciencesNCT01304706Written as Fluocinolone AcetonideHow we know
- Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior SegmentCompletedPhase 4Duke UniversityNCT00543296Written as 0.59 mg Fluocinolone Acetonide implantHow we know
- Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular EdemaCompletedPhase 3Alimera SciencesNCT00344968Written as fluocinolone acetonideHow we know
See all 28 studies that test Fluocinolone Acetonide →
Given beside what is tested · 1 — Fluocinolone Acetonide is usual care or a partner of the new treatment
Codes
What other systems call Fluocinolone Acetonide · ClinicalTrials.gg INT007504
- MeSH (NLM) D005446Fluocinolone AcetonideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0CD5FD6S2MFLUOCINOLONE ACETONIDEConfirmed FDA, NLM, Wikidata
- RxNorm 4461Confirmed FDA, Wikidata
- Wikidata Q924467fluocinolone acetonideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29055Fluocinolone AcetonideOne source FDA
- DrugBank DB00591One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005446 | Fluocinolone Acetonide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0CD5FD6S2M | FLUOCINOLONE ACETONIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 4461 | — | Confirmed FDA, Wikidata |
| Wikidata | Q924467 | fluocinolone acetonide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29055 | Fluocinolone Acetonide | One source FDA |
| DrugBank | DB00591 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.